TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06390332

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Giving Information for Trauma Support and Safety (GIFTSS) Training
Description: Training for college health center staff and clinicians on GIFTSS intervention which is a universal education and brief counseling to address sexual violence prevention and intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Giving Information for Trauma Support and Safety (GIFTSS) Training
Description: Training for college health center staff and clinicians on GIFTSS intervention which is a universal education and brief counseling to address sexual violence prevention and intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Centering gender Affirming Resources in higher Education (CARE) Learning Modules
Description: Training for college health center clinicians and staff on trans and gender diverse (TGD) affirming clinical practices in addition to sexual violence and alcohol abuse prevention that is inclusive of TGD service users
Study: NCT05387980

Intervention type: DRUG
Intervention: CIBINQO
Description: Patients receiving CIBINQO tablets by mouth for the treatment of Atopic Dermatitis.
Study: NCT06455527

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcranial Direct Current Stimulation (tDCS)
Description: tDCS will be delivered using the 1x1 Mini CT tDCS device. For active tDCS, the device is programmed to ramp up to 2.0 mA (for 30 seconds), provide constant current throughout the session (29 minutes), and then ramp down (for 30 seconds) at the end. Participants will receive 10 sessions of tDCS over the course of this study on weekdays (M-F).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation (tDCS)
Description: Sham tDCS will be delivered using the 1x1 Mini CT tDCS device. For sham tDCS, the device is programmed to ramp up to 2.0 mA (for 30 seconds) followed by a ramp down (30 seconds), with no current delivery for 28 minutes, and then ramp up (for 30 seconds) and down (for 30 seconds) at the end. Participants will receive 10 sessions of sham tDCS over the course of this study on weekdays (M-F).
Study: NCT05127447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ES application
Description: Electrical stimulation (ES) application will be given to the ES group

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham application
Description: Only vacuum was applied and no current was given from the applied device
Study: NCT05630612

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sparsentan
Description: 6 weeks of treatment with sparsentan or irbesartan. This will be administered in a double-blind fashion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sparsentan
Description: 6 weeks of treatment with sparsentan or irbesartan. This will be administered in a double-blind fashion.
Study: NCT05237908

Intervention type: DEVICE
Intervention: Transforaminal Lumbar Interbody Fusion
Description: Interbody Fusion means the operative immobilization or ankylosis of two or more vertebrae by fusion of the vertebral bodies with a short bone graft or often with diskectomy or laminectomy. (From Blauvelt and Nelson, A Manual of Orthopaedic Terminology, 5th ed, p236; Dorland, 28th ed

Intervention type: DEVICE
Intervention: Transforaminal Lumbar Interbody Fusion
Description: Interbody Fusion means the operative immobilization or ankylosis of two or more vertebrae by fusion of the vertebral bodies with a short bone graft or often with diskectomy or laminectomy. (From Blauvelt and Nelson, A Manual of Orthopaedic Terminology, 5th ed, p236; Dorland, 28th ed
Study: NCT05423652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung point of care ultrasound
Description: Point of care ultrasound of the lungs will be performed to enhance physical assessments as needed to make clinical decisions for patients with CHF, COPD and/or pneumonia. The majority of images will be acquired and uploaded to a web-based portal by community paramedics in patients' homes and interpreted remotely by hospital-based physicians on call for the home hospital.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRESUNA software
Description: PRESUNA is a new medical software that enables clinicians to summarize POCUS findings and document them on a platform that provides a visual summary of findings over time. PRESUNA also provides POCUS educators and learners to see the learners' progress over time in terms of the accuracy of their assessments when compared to POCUS experts providing longitudinal mentorship.
Study: NCT04183023

Intervention type: GENETIC
Intervention: Collection of a salivary sample
Description: Volunteers who agreed to participate will have to collect their saliva with the self-collection device. They will then send back their saliva sample and a dated and signed copy of the informed consent form in the pre-paid return envelope.~All DNA of the saliva samples will be automatically extracted, then DNA samples will be genotyped and 4,000 of them will be sequenced.~The genotyping will consist of measurement of general genetic variation, including the Single Nucleotide Polymorphisms. The SNP genotyping will be carried out using Illumina high density chips, in CNRGH production platform.~A subset of 4,000 individuals will be selected to provide a homogeneous geographic coverage and to avoid inclusion of related individuals who will share large genomic regions. Sequencing will be performed in order to reach a mean coverage of 30X for each sample and a minimum of 25X mean coverage.~Finally, a bioinformatics analysis will be performed on sequencing data.
Study: NCT05575687

Intervention type: OTHER
Group type: OTHER
Intervention: Water (reference)
Description: Ingestion of 500 ml mineral water

Intervention type: OTHER
Group type: OTHER
Intervention: Sucrose
Description: Ingestion of 500 ml of a flavored mineral water sweetened with sucrose

Intervention type: OTHER
Group type: OTHER
Intervention: Sucralose
Description: Ingestion of 500 ml of a flavored mineral water sweetened with sucralose

Intervention type: OTHER
Group type: OTHER
Intervention: Stevia
Description: Ingestion of 500 ml of a flavored mineral water sweetened with stevia extract

Intervention type: OTHER
Group type: OTHER
Intervention: Monk fruit
Description: Ingestion of 500 ml of a flavored mineral water sweetened with monk fruit extract

Intervention type: OTHER
Group type: OTHER
Intervention: Allulose + stevia
Description: Ingestion of 500 ml of a flavored mineral water sweetened with allulose and stevia extract
Study: NCT06038747

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Monitoring
Description: The post-session battery consists of two self-report scales measuring both positive and negative affective reactions of the participants toward their therapist during the therapy session. The general feedback is a brief text that encourages participants to share and discuss their feelings and reflections with their therapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual Psychotherapy
Description: Individual psychotherapy sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual Psychotherapy
Description: Individual psychotherapy sessions
Study: NCT06294145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Savoring Intervention
Description: The savoring intervention is the first module of the Positive Affect Treatment (PAT) developed by Michelle Craske and colleagues to treat anhedonia, or loss of interest or pleasure in usual activities. The investigators focus here on the behavioral activation and savoring components of the intervention, which are administered first and are considered the basis for other components. Of note, a variety of other positive psychology interventions include a savoring component, but PAT is unique in its inclusion of six sessions devoted to savoring. These sessions involve pleasant events scheduling in which participants: 1) plan activities that generate anticipation of reward, 2) engage in activities that generate reward and 3) practice therapist-guided-in-the-moment recounting of positive emotions, sensations, and thoughts generated by these activities. The investigators will additionally include an introductory psychoeducation session before the savoring module, as PAT does.
Study: NCT04909619

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral suprazygomatic maxillary nerve block
Description: The maxillary nerve, V2, is purely a sensory branch of the trigeminal nerve. V2 exits the skull through the foramen rotundum and courses through the pterygopalatine fossa, a small pyramid-shaped depression located posterior to the maxilla. As the maxillary nerve exits the pterygopalatine fossa, it divides into numerous branches that supply sensation to the posterior nasal cavity, palate, sinuses, and maxilla. It is within the pterygopalatine fossa that the maxillary nerve is targeted and anesthetized during the block. With the patient in the supine position after nasotracheal intubation, a needle is inserted perpendicularly between the upper border of the zygomatic arch and posterior orbital rim until it reaches the greater wing of the sphenoid, where the needle is then retracted by a few millimeters and redirected toward the nasolabial fold until it hits the pterygopalatine fossa.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic infiltration of the palate
Description: Local anesthetic infiltration of the palate during cleft palate repair is universally practiced. The benefits of local anesthetic infiltration are twofold: to provide anesthesia to the terminal branches of the nasopalatine and greater palatine nerves that are in the immediate area of the injection sites and to achieve hemostasis during closure when the medication is mixed with epinephrine. To administer local anesthetic infiltration of the palate, a 25 gauge needle is inserted next to the incision into the soft tissue. The tissue is first aspirated to determine safety of injection at that site. The medication is then injected parallel to the incision on both sides.
Study: NCT04300764

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamification Intervention
Description: Intervention participants will receive daily text messages to help them set goals, receive feedback and support on their progress towards daily goals, and receive points for daily goals achieved. Each participant will be given a Fitbit watch that will transmit data to the Way to Health study platform. Data will be passively collected during the inpatient stay and for 30 days after hospital discharge.
Study: NCT04756271

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-Cov-2 neutralizing antibody titer
Description: Quantitation of SARS-Cov-2 antibody titer at baseline after each dose of the vaccine
Study: NCT05841615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Renal Denervation operation
Description: RDN: Percutaneous renal artery sympathetic radiofrequency ablation for both sides. For each side, a total of 13 targets were ablated. The ablation power was 8W\~12W for 40 seconds
Study: NCT06309251

Intervention type: OTHER
Intervention: ketogenic diet (as per clinical practice)
Description: Patients recruited receive a ketogenic diet. The prescription, the type of KD protocol and the route of administration will depend, essentially, on the patient's ability and willingness to feed spontaneously and independently, as well as on compliance with the therapies set and the severity of the clinical conditions.
Study: NCT06647459

Intervention type: DIAGNOSTIC_TEST
Intervention: EP Study
Description: To use programmed ventricular stimulation at the time of AF ablation to define the prevalence and mechanism of inducible ventricular tachycardia (VT); pace-mapping to define the site of origin of ventricular arrhythmias; and voltage mapping to define low voltage scar substrate in the basal LV in patients with pathogenic TTN variants compared to genotype-negative controls.

Intervention type: DIAGNOSTIC_TEST
Intervention: EP Study
Description: To use programmed ventricular stimulation at the time of AF ablation to define the prevalence and mechanism of inducible ventricular tachycardia (VT); pace-mapping to define the site of origin of ventricular arrhythmias; and voltage mapping to define low voltage scar substrate in the basal LV in patients with pathogenic TTN variants compared to genotype-negative controls.

Intervention type: DIAGNOSTIC_TEST
Intervention: EP Study
Description: To use programmed ventricular stimulation at the time of AF ablation to define the prevalence and mechanism of inducible ventricular tachycardia (VT); pace-mapping to define the site of origin of ventricular arrhythmias; and voltage mapping to define low voltage scar substrate in the basal LV in patients with pathogenic TTN variants compared to genotype-negative controls.
Study: NCT04450966

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-facilitated Screening and Brief Intervention
Description: cSBI includes: 1) computer self-administered screening that adolescents complete prior to seeing their clinician, immediately followed by 2) computer-delivered brief psychoeducation on the health risks of substance use to prime patients for the clinician encounter, and 3) a Clinician Report Form with screen results and prompts that clinicians use to provide motivational interviewing-based individualized counseling during the visit.
Study: NCT06274723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expert
Description: Participants will view a brief description of an expert source.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer
Description: Participants will view a brief description of a peer source.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 Sided
Description: Participants will view e-cigarette education messages in one-sided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 Sided
Description: Participants will view e-cigarette education messages in two-sided.
Study: NCT05255393

Intervention type: OTHER
Intervention: Questionnaires
Description: A 13-item questionnaire specific to LEL, developed and validated by investigators at the Mayo Clinic.~The EORTC QLQ-C30 is a 30-item questionnaire designed to assess the quality of life of cancer patients.~The EORTC Quality of Life - Cervical Cancer Module.

Intervention type: OTHER
Intervention: Questionnaires
Description: A 13-item questionnaire specific to LEL, developed and validated by investigators at the Mayo Clinic.~The EORTC QLQ-C30 is a 30-item questionnaire designed to assess the quality of life of cancer patients.~The EORTC Quality of Life - Cervical Cancer Module.
Study: NCT06384131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABI-4334
Description: 10 mg or 50 mg tablets for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mg or 50 mg tablets for oral administration
Study: NCT05603052

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EuCorVac-19
Description: COVID-19 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EuCorVac-19
Description: COVID-19 vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAdOx1 nCoV-19
Description: COVID-19 vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAdOx1 nCoV-19
Description: COVID-19 vaccine
Study: NCT04863248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: Trilaciclib administered IV over 30 minutes prior to docetaxel IV on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered IV over 30 minutes prior to docetaxel IV on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel administered IV on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel administered IV on Day 1 of each 21-day cycle.
Study: NCT05756114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support Group
Description: Support Group condition, meetings will be held online via HIPAA-compliant Zoom and run by a trained SMART Recovery meeting facilitator

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational Email
Description: Participants receive a weekly email with a Qualtrics survey link containing psychoeducational content.
Study: NCT05192629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Premedication by intranasal dexmedetomidine
Study: NCT05841615

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Pulmonary vein isolation
Description: PVI: Pulmonary vein isolation was performed until the potential of each pulmonary vein disappeared under the guidance of the CARTO mapping system. Ablation of the top line and the bottom line of the left atrium was performed at the same time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation
Description: PVI: Pulmonary vein isolation was performed until the potential of each pulmonary vein disappeared under the guidance of the CARTO mapping system. Ablation of the top line and the bottom line of the left atrium was performed at the same time.
Study: NCT05192629

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Premedication by intranasal midazolam
Study: NCT05830656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to nearby nature
Description: Participants spend a minimum of 20 minutes in their favourite place in nearby nature.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to nearby nature
Description: Participants spend a minimum of 20 minutes in their favourite place in nearby nature.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to virtual nature
Description: Participants spend a minimum of 20 minutes watching virtual nature videos.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to virtual nature
Description: Participants spend a minimum of 20 minutes watching virtual nature videos.
Study: NCT05924750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-M11D1
Description: Administration by intravenous infusion
Study: NCT06395974

Intervention type: OTHER
Intervention: fetal ultrasound
Description: 2D, 3D , Doppler ultrasound

Intervention type: OTHER
Intervention: fetal ultrasound
Description: 2D, 3D , Doppler ultrasound
Study: NCT06136702

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational session
Description: A community-based researcher will educate women about sexual health and cervical cancer by using the materials that will be developed by the ELEVATE team. Women will be informed about cervical cancer screening (pap smear) and about where they can obtain these services off-site (health facilities). Furthermore, a self-administrated questionnaire is applied to assess current knowledge, willingness to get screened (clinically collected sample) and uptake.
Study: NCT05727631

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gentle human touch
Description: Mother will apply gentle human touch touch technique during venous blood collection from preterm babies between 32-37 weeks of gestation
Study: NCT06136702

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational session
Description: A community-based researcher will educate women about sexual health and cervical cancer by using the materials that will be developed by the ELEVATE team. Women will be informed about cervical cancer screening (pap smear) and about where they can obtain these services off-site (health facilities). Furthermore, a self-administrated questionnaire is applied to assess current knowledge, willingness to get screened (clinically collected sample) and uptake.
Study: NCT06605235

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Anesthesia
Description: In Group A, patients received 20 ml of 1% lignocaine (Xyloaid-lignocaine HCl injection) infiltrated in the gall bladder bed after removal of the gall bladder, along with 10 ml of 1% lignocaine infiltration at the port sites at the end of the procedure. Subjects in Group B received 20 ml of 0.25% bupivacaine (Bupicain-Bupivacaine HCl injection) infiltration in gall bladder bed, along with 10 ml of 0.25% bupivacaine at port sites. In Group C patients received 10 ml of 1% lignocaine along with 10 ml of 0.25% bupivacaine infiltrated in gall bladder bed, and then 5 ml of 1% lignocaine along with 5 ml of 0.25% bupivacaine at the port sites

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Anesthesia
Description: In Group A, patients received 20 ml of 1% lignocaine (Xyloaid-lignocaine HCl injection) infiltrated in the gall bladder bed after removal of the gall bladder, along with 10 ml of 1% lignocaine infiltration at the port sites at the end of the procedure. Subjects in Group B received 20 ml of 0.25% bupivacaine (Bupicain-Bupivacaine HCl injection) infiltration in gall bladder bed, along with 10 ml of 0.25% bupivacaine at port sites. In Group C patients received 10 ml of 1% lignocaine along with 10 ml of 0.25% bupivacaine infiltrated in gall bladder bed, and then 5 ml of 1% lignocaine along with 5 ml of 0.25% bupivacaine at the port sites

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Anesthesia
Description: In Group A, patients received 20 ml of 1% lignocaine (Xyloaid-lignocaine HCl injection) infiltrated in the gall bladder bed after removal of the gall bladder, along with 10 ml of 1% lignocaine infiltration at the port sites at the end of the procedure. Subjects in Group B received 20 ml of 0.25% bupivacaine (Bupicain-Bupivacaine HCl injection) infiltration in gall bladder bed, along with 10 ml of 0.25% bupivacaine at port sites. In Group C patients received 10 ml of 1% lignocaine along with 10 ml of 0.25% bupivacaine infiltrated in gall bladder bed, and then 5 ml of 1% lignocaine along with 5 ml of 0.25% bupivacaine at the port sites
Study: NCT06605261

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga (intervention) group
Description: The yoga (intervention) group comprises 64 women with breast cancer who have been randomly assigned and are undergoing endocrine therapy. To alleviate arthralgia and vasomotor symptoms (hot flashes, night sweats), a structured yoga program will be administered during the initial months of endocrine therapy, consisting of 60-minute sessions, 4 days per week, for a duration of one month.
Study: NCT04739800

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood